151 related articles for article (PubMed ID: 15986134)
41. Wnt signaling and orthopedic diseases.
Ishikawa Y
Am J Pathol; 2005 Jul; 167(1):1-3. PubMed ID: 15972946
[No Abstract] [Full Text] [Related]
42. Secreted WNT antagonists as tumor suppressors: pro and con.
Rubin JS; Barshishat-Kupper M; Feroze-Merzoug F; Xi ZF
Front Biosci; 2006 Sep; 11():2093-105. PubMed ID: 16720296
[TBL] [Abstract][Full Text] [Related]
43. Focus on molecules: SFRP1.
Mao W; Wordinger RJ; Clark AF
Exp Eye Res; 2010 Nov; 91(5):552-3. PubMed ID: 20478307
[No Abstract] [Full Text] [Related]
44. WNT Signaling in Melanoma.
Gajos-Michniewicz A; Czyz M
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32659938
[TBL] [Abstract][Full Text] [Related]
45. Growth factors and oncogenes as targets in melanoma: lost in translation?
Kwong L; Chin L; Wagner SN
Adv Dermatol; 2007; 23():99-129. PubMed ID: 18159898
[TBL] [Abstract][Full Text] [Related]
46. In the Wnt-er of life: Wnt signalling in melanoma and ageing.
Kaur A; Webster MR; Weeraratna AT
Br J Cancer; 2016 Nov; 115(11):1273-1279. PubMed ID: 27764844
[TBL] [Abstract][Full Text] [Related]
47. Wnt, a driver of myocardialization?
van den Hoff MJ; Moorman AF
Circ Res; 2005 Feb; 96(3):274-6. PubMed ID: 15718507
[No Abstract] [Full Text] [Related]
48. Frizzled receptors in melanomagenesis: From molecular interactions to target identification.
Umar SA; Dong B; Nihal M; Chang H
Front Oncol; 2022; 12():1096134. PubMed ID: 36620565
[TBL] [Abstract][Full Text] [Related]
49. Multiple roles of canonical Wnt signaling in cell cycle progression and cell lineage specification in neural development.
Sommer L
Cell Cycle; 2004 Jun; 3(6):701-3. PubMed ID: 15118414
[TBL] [Abstract][Full Text] [Related]
50. [Beta-catenin and N-ras: a dangerous association for melanocytes].
Bertolotto C
Med Sci (Paris); 2008 Feb; 24(2):122-3. PubMed ID: 18272065
[No Abstract] [Full Text] [Related]
51. Pathways to the development of melanoma: a complex issue.
Berwick M
J Invest Dermatol; 2006 Sep; 126(9):1932-3. PubMed ID: 16912689
[TBL] [Abstract][Full Text] [Related]
52. Linking cilia to Wnts.
Germino GG
Nat Genet; 2005 May; 37(5):455-7. PubMed ID: 15858588
[No Abstract] [Full Text] [Related]
53. Plasticity of the cancer cell: implications for epigenetic control of melanoma and other malignancies.
Lipkin G
J Invest Dermatol; 2008 Sep; 128(9):2152-5. PubMed ID: 18401428
[TBL] [Abstract][Full Text] [Related]
54. The complex pathways of Wnt 5a in cancer progression.
Pukrop T; Binder C
J Mol Med (Berl); 2008 Mar; 86(3):259-66. PubMed ID: 17952396
[TBL] [Abstract][Full Text] [Related]
55. Hypothesis: a role for telomere crisis in spontaneous regression of melanoma.
Bastian BC
Arch Dermatol; 2003 May; 139(5):667-8. PubMed ID: 12756110
[No Abstract] [Full Text] [Related]
56. Seasonal variation in melanoma progress.
Akslen LA
J Natl Cancer Inst; 1995 Jul; 87(13):1025-6. PubMed ID: 7629877
[No Abstract] [Full Text] [Related]
57. Regulation of Wnt Signaling Pathways at the Plasma Membrane and Their Misregulation in Cancer.
Azbazdar Y; Karabicici M; Erdal E; Ozhan G
Front Cell Dev Biol; 2021; 9():631623. PubMed ID: 33585487
[TBL] [Abstract][Full Text] [Related]
58. Wnt Signaling Pathways in Keratinocyte Carcinomas.
Lang CMR; Chan CK; Veltri A; Lien WH
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31438551
[TBL] [Abstract][Full Text] [Related]
59. Integrins and melanoma progression.
Danen EH; van Muijen GN; ten Berge PJ; Ruiter DJ
Recent Results Cancer Res; 1993; 128():119-32. PubMed ID: 8356314
[No Abstract] [Full Text] [Related]
60. Growth factor signalling pathways in cancer progression: complexities and therapeutic opportunities. Proceedings of the 2nd Tenovus/AstraZeneca Workshop. April 20-21, 2006. Cardiff, United Kingdom.
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S1-135. PubMed ID: 17259551
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
